Health

STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 21/10/2026, 08:36:25 UTC.

Briefings

A German biotech presented Phase 1 results at the European oncology conference in October 2025, showing that a single experimental cell therapy successfully shrunk tumors in 16 patients with rare uveal melanoma. The data suggested the therapy could potentially unlock immunotherapy benefits for common cancers like pancreatic and ovarian tumors, though this remains preliminary. The presentation was highlighted as a potential breakthrough for oncology, with experts noting the need to move forward with other areas of the field.

Key points

• A German biotech presented Phase 1 clinical trial results at the European oncology conference in October 2025.
• The trial involved 16 patients with uveal melanoma who showed tumor shrinkage after receiving an experimental cell therapy.

Context

The presentation occurred at the most important European oncology conference, where standard practice involves large-scale clinical trials. This event was notable for its small sample size of 16 patients, contrasting with typical large-scale trials. The findings suggest potential applications in other common cancers, though the study is still in early phases.

Limitations

The evidence is limited to a single presentation at a specific conference in October 2025. The study is described as preliminary, with no long-term data or broader patient outcomes provided. The specific mechanism of action and long-term efficacy remain unverified.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 21/10/2026, 08:37:36 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihwehb4o3cfecobsqebm6i346cw4co4evv2nr7767mhw56m53mquu